Bicocca Open Archive

Logo unimib boa
CORTINOVIS, DIEGO LUIGI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.377
EU - Europa 4.261
AS - Asia 2.588
SA - Sud America 170
AF - Africa 25
Continente sconosciuto - Info sul continente non disponibili 6
OC - Oceania 4
Totale 13.431
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.295
SG - Singapore 1.091
RU - Federazione Russa 996
IT - Italia 874
HK - Hong Kong 770
IE - Irlanda 687
DE - Germania 621
CN - Cina 390
SE - Svezia 376
UA - Ucraina 172
BR - Brasile 158
ID - Indonesia 138
GB - Regno Unito 127
AT - Austria 103
FI - Finlandia 83
CA - Canada 77
NL - Olanda 55
FR - Francia 52
IN - India 47
DK - Danimarca 38
JP - Giappone 27
TR - Turchia 26
BE - Belgio 24
VN - Vietnam 19
KR - Corea 12
PL - Polonia 11
ZA - Sudafrica 11
CZ - Repubblica Ceca 8
IQ - Iraq 8
BD - Bangladesh 7
JO - Giordania 7
TW - Taiwan 6
IR - Iran 5
AZ - Azerbaigian 4
EU - Europa 4
UZ - Uzbekistan 4
AL - Albania 3
AR - Argentina 3
BG - Bulgaria 3
GR - Grecia 3
RO - Romania 3
SA - Arabia Saudita 3
SK - Slovacchia (Repubblica Slovacca) 3
AE - Emirati Arabi Uniti 2
AM - Armenia 2
AU - Australia 2
CH - Svizzera 2
CL - Cile 2
EC - Ecuador 2
EG - Egitto 2
ES - Italia 2
HU - Ungheria 2
IL - Israele 2
LK - Sri Lanka 2
LU - Lussemburgo 2
MA - Marocco 2
MT - Malta 2
MU - Mauritius 2
MX - Messico 2
NP - Nepal 2
NZ - Nuova Zelanda 2
PH - Filippine 2
PK - Pakistan 2
PS - Palestinian Territory 2
PT - Portogallo 2
TH - Thailandia 2
UY - Uruguay 2
A1 - Anonimo 1
A2 - ???statistics.table.value.countryCode.A2??? 1
BO - Bolivia 1
CO - Colombia 1
CY - Cipro 1
DZ - Algeria 1
ET - Etiopia 1
GN - Guinea 1
HR - Croazia 1
KE - Kenya 1
KG - Kirghizistan 1
KH - Cambogia 1
KW - Kuwait 1
LT - Lituania 1
LV - Lettonia 1
MD - Moldavia 1
MK - Macedonia 1
MY - Malesia 1
NG - Nigeria 1
NO - Norvegia 1
PA - Panama 1
PE - Perù 1
PR - Porto Rico 1
SC - Seychelles 1
SI - Slovenia 1
SN - Senegal 1
TJ - Tagikistan 1
TN - Tunisia 1
TT - Trinidad e Tobago 1
Totale 13.431
Salva come PNG Salva come JPEG
Città #
Ann Arbor 1.270
Hong Kong 762
Singapore 684
Dublin 666
Fairfield 533
Woodbridge 411
Frankfurt am Main 373
Chandler 360
Ashburn 340
Wilmington 302
New York 265
Houston 231
Milan 226
Seattle 216
Cambridge 208
Santa Clara 199
Jacksonville 168
Princeton 146
Jakarta 136
Dearborn 125
Vienna 80
Shanghai 76
Lawrence 66
Altamura 57
Nuremberg 50
Moscow 49
Nanjing 48
Boardman 47
Turin 47
Helsinki 46
London 45
San Diego 44
Beijing 35
Rome 35
Guangzhou 34
Toronto 26
Andover 25
Lachine 25
Los Angeles 25
Brussels 24
Council Bluffs 24
São Paulo 19
Chicago 18
Munich 16
Ottawa 16
Hebei 15
Monza 15
Tianjin 15
Assago 14
Dong Ket 14
Jinan 14
Pune 14
Dallas 13
Falls Church 13
Florence 13
Nanchang 12
Tokyo 12
Amsterdam 11
Hangzhou 11
Shenyang 11
Bergamo 10
Genoa 10
Lappeenranta 10
Norwalk 10
Bari 9
Bologna 9
Düsseldorf 9
Lissone 9
Lodi 8
Naples 8
Rio de Janeiro 8
Seregno 8
Edmonton 7
Fremont 7
Lauterbourg 7
Zhengzhou 7
Bonndorf 6
Cesano Maderno 6
Changsha 6
Huizen 6
Kunming 6
Mountain View 6
Ningbo 6
Redmond 6
Torre Del Greco 6
Baghdad 5
Brno 5
Carate Brianza 5
Carignano 5
Como 5
Hefei 5
Lodz 5
Newark 5
Perugia 5
Phoenix 5
Portsmouth 5
Reston 5
Segrate 5
Torino 5
Alessandria 4
Totale 9.059
Salva come PNG Salva come JPEG
Nome #
p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma 346
A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib 275
Evaluation of the psychometric properties of the EORTC chemotherapy-induced peripheral neuropathy questionnaire (QLQ-CIPN20) 261
Validation of the Italian version of the full and abbreviated Trust in Oncologist Scale 254
Risk stratification of oxaliplatin induced peripheral neurotoxicity applying electrophysiological testing of dorsal sural nerve 244
Indicators of guideline-concordant care in lung cancer defined with a modified Delphi method and piloted in a cohort of over 5,800 cases 241
Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS) 227
Genetic determinants of chronic oxaliplatin-induced peripheral neurotoxicity: A genome-wide study replication and meta-analysis 224
The Reproducibility of the Immunohistochemical PD-L1 Testing in Non-Small-Cell Lung Cancer: A Multicentric Italian Experience 221
Neuropathic pain and chemotherapy-induced peripheral neurotoxicity: the issue 194
Incidence of atypical acute nerve hyperexcitability symptoms in oxaliplatin-treated patients with colorectal cancer 193
The "digital biopsy" in non-small cell lung cancer (NSCLC): a pilot study to predict the PD-L1 status from radiomics features of [18F]FDG PET/CT 193
Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients 191
Chemotherapy-Induced Peripheral Neurotoxicity assessment: a critical revision of the currently available tools 190
Correspondence between neurophysiological and clinical measurements of chemotherapy-induced peripheral neuropathy: secondary analysis of data from the CI-PeriNoms study 189
C-arm cone-beam CT-guided transthoracic lung core needle biopsy as a standard diagnostic tool 188
Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin 185
Advanced age and liability to oxaliplatin-induced peripheral neuropathy: post hoc analysis of a prospective study 180
Rasch-Transformed Total Neuropathy Score clinical version (RT-TNSc©) in patients with chemotherapy-induced peripheral neuropathy 177
A Longitudinal Study on Oxaliplatin Induced Peripheral Neuropathy – Incidence and Facts About the “Real Life” Population And Actual Dose 173
Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: Results from a prospective multicenter study 169
Lack of Bax expression is associated with irinotecan-based treatment activity in advanced colorectal cancer patients 169
RNA-Based Assay for Next-Generation Sequencing of Clinically Relevant Gene Fusions in Non-Small Cell Lung Cancer 168
Vanishing bile duct syndrome following pembrolizumab infusion: case report and review of the literature 168
Neuroprotectant agents against oxaliplatin induced neurotoxicity: lackings, facts and future prospective 166
Efficacy of a Novel Sigma-1 Receptor Antagonist for Oxaliplatin-Induced Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Clinical Trial 166
MR309/E-52862, a first-in-class sigma-1 receptor antagonist, in oxaliplatin-induced peripheral neuropathy. An exploratory Phase II clinical trial 162
Dorsal sural nerve conduction study in the assessment of oxaliplatin induced peripheral neuropathy 161
Metabolic parameters as biomarkers of response to immunotherapy and prognosis in non-small cell lung cancer (Nsclc): A real world experience 161
Incidence, characteristics, and associations of oxaliplatin-induced peripheral neuropathy in colorectal cancer patients: Results of a prospective, multicenter, international study. 160
Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients 158
The Association between Vitamin D and Gut Microbiota: A Systematic Review of Human Studies 157
The significance of dorsal sural nerve recordings in early detecting oxaliplatin-induced peripheral neuropathy. 154
When progressive dysphagia could be related to an “old friend” – a case report 153
Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin 152
Long-term course of oxaliplatin-induced polyneuropathy: a prospective two-year follow-up study 152
Major issue in chemotherapy-induced peripheral neuropathy (cipn): lack of standardized measurement scales. ciperinoms study: validity and reliability in cipn assessment 136
Peritoneal carcinomatosis in non-small-cell lung cancer: retrospective multicentric analysis and literature review 133
Vitamin D supplementation and cancer mortality: Narrative review of observational studies and clinical trials 130
RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients 129
Novel cytotoxic chemotherapies in small cell lung carcinoma 124
Clinical pattern and associations of oxaliplatin acute neurotoxicity: A prospective study in 170 patients with colorectal cancer 123
New pan-ALK inhibitor-resistant EML4::ALK mutations detected by liquid biopsy in lung cancer patients 122
High Prevalence and Early Occurrence of Skeletal Complications in EGFR Mutated NSCLC Patients With Bone Metastases 112
Isotretinoin plus clindamycin seem highly effective against severe erlotinib-induced skin rash in advanced non-small cell lung cancer 111
Thymus neuroendocrine tumors with CTNNB1 gene mutations, disarrayed ß-catenin expression, and dual intra-tumor Ki-67 labeling index compartmentalization challenge the concept of secondary high-grade neuroendocrine tumor: a paradigm shift 110
New advances in liquid biopsy technologies for anaplastic lymphoma kinase (Alk)—positive cancer 105
ALK determination: Liquid and tissue biopsy. Comparing techniques and effectiveness of alectinib in a controversial clinical case [Determinazione di ALK: Tra biopsia liquida e tissutale. Tecniche a confronto ed efficacia di alectinib in un caso clinico controverso] 103
Disseminated intravascular coagulation in advanced lung adenocarcinoma during first-line pembrolizumab 103
Novel ALK mutations in EML4::ALK+ NSCLC resistant to TKIs identified by liquid biopsy 100
Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients Aged ≥ 75 Years With Non–small-cell Lung Cancer (NSCLC): An Italian, Multicenter, Retrospective Study 99
Efficacy and Safety of the All-Oral Schedule of Metronomic Vinorelbine and Capecitabine in Locally Advanced or Metastatic Breast Cancer Patients: The Phase I-II VICTOR-1 Study 93
Focus on nivolumab in NSCLC 92
Trabectedin in Malignant Pleural Mesothelioma: Results From the Multicentre, Single Arm, Phase II ATREUS Study 89
Clinical treatment of cholangiocarcinoma: an updated comprehensive review 88
Vitamin D and SARS-CoV2 infection, severity and mortality: A systematic review and meta-analysis 88
Phase I study of escalating doses of oxaliplatin in combination with fixed dose gemcitabine in patients with non-small cell lung cancer 88
Oxaliplatin doublets in non-small cell lung cancer: A literature review 84
Is irinotecan plus docetaxel useful as second-line therapy in advanced non-small cell lung cancer? 82
An Overview of PARP Resistance in Ovarian Cancer from a Molecular and Clinical Perspective 80
FHIT and p53 status and response to platinum-based treatment in advanced non-small cell lung cancer 77
A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose cisplatin 75
Epidermal growth factor receptor exon 20 insertion variants in non-small cell lung cancer patients 74
Targeted therapies and immunotherapy in non-small-cell lung cancer 72
Randomized phase II three-arm trial with three platinum-based doublets in metastatic non-small-cell lung cancer. An Italian Trials in Medical Oncology study 71
Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial 70
Preclinical and clinical evaluation of four gemcitabine plus carboplatin schedules as front-line treatment for stage IV non-small-cell lung cancer 68
Isolated cardiac metastasis from squamous cell esophageal cancer 68
Treatment patterns, clinical outcomes and healthcare costs of advanced non-small cell lung cancer: A real-world evaluation in Italy 68
Efficacy and safety of vinorelbine-capecitabine oral metronomic combinaton in elderly metastatc breast cancer patents: VICTOR-1 study 67
Diagnostic and prognostic biomarkers in oligometastatic non-small cell lung cancer: A literature review 64
Gemcitabine-induced thrombocytosis as a potential predictive factor in non-small cell lung cancer: Analysis of 318 patients 63
Aplastic anemia in a patient with advanced lung adenocarcinoma during first line osimertinib: A case report and literature review 63
Challenges in ALK inhibition of ALK-positive non-small-cell lung cancer: From ALK positivity detection to treatment strategies after relapse 62
Single-agent chemotherapy with vinorelbine for pretreated or metastatic squamous cell carcinoma of the esophagus 62
What are the options for non-small-cell lung cancer patients post second-line therapy? 61
Economic assessment of NGS testing workflow for NSCLC in a healthcare setting 59
Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer 59
Sneaky Diagnosis of Pleural Malignant Mesothelioma in Thoracic Surgery: All That Glitters Is Not Gold 56
VITAMIN D SUPPLEMENTATION MAY IMPROVE COVID-19 PROGNOSIS? EVIDENCE FROM A SYSTEMATIC REVIEW AND META-ANALYSIS 55
Immune-Checkpoint-Inhibitor-Related Lung Toxicity: A Multicentre Real-Life Retrospective Portrait from Six Italian Centres 54
Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer 53
Overall and disease-free survival greater than 12 years in metastatic non-small cell lung cancer after linear accelerator-based stereotactic radiosurgery for solitary brain metastasis 52
Harnessing DLL3 inhibition: From old promises to new therapeutic horizons 51
Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma 51
Interpretation of lung cancer study outcomes 50
Recommendations for a practical implementation of circulating tumor DNA mutation testing in metastatic non-small-cell lung cancer 46
Project R. Evolution for improving clinical research in Italy: challenges and strategies 46
A new race against lung cancer 44
Integrated therapeutic strategies for anaplastic thyroid carcinoma 44
Immunotherapy in Underrepresented Populations of Patients with Cancer: Do We Have Enough Evidence at Present? A Focus on Patients with Major Viral Infections and Autoimmune Disorders 43
RNA-based next-generation sequencing in non-small-cell lung cancer in a routine setting: an experience from an Italian referral center 41
The biomarkers ATLAS: An audit on 1100 non-small cell lung cancer from an Italian knowledge-based database 41
Novel Therapeutic Options for Small Cell Lung Cancer 41
Final results of DIADEM, a phase II study to investigate the efficacy and safety of durvalumab in advanced pretreated malignant pleural mesothelioma 41
Elapsed time for an unresolved adverse event: systemic anticancer therapy-induced neurotoxicity calls for action 40
Pulmonary carcinoid tumours: indolent but not benign 40
The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer 40
Atezolizumab Versus Docetaxel in Pretreated Patients With NSCLC: Final Results From the Randomized Phase 2 POPLAR and Phase 3 OAK Clinical Trials 40
Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non–Small Cell Lung Cancer 38
Totale 11.656
Salva come PNG Salva come JPEG
Categoria #
all - tutte 66.702
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 66.702
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020279 0 0 0 0 0 0 0 0 0 118 128 33
2020/20211.499 76 62 151 133 87 94 152 178 142 155 126 143
2021/20221.108 102 144 159 114 64 77 50 42 55 58 82 161
2022/20231.743 211 504 138 184 112 244 24 117 113 39 43 14
2023/20242.515 45 44 45 64 588 530 444 77 309 57 47 265
2024/20254.437 312 712 289 252 541 217 537 207 656 714 0 0
Totale 14.287